{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-23-000152","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.712401+00:00","generated_at":"2026-06-12T01:16:26.236111+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Emergent BioSolutions Q2 revenue $338M beats guidance; net loss $261M on $307M impairment; FY guidance cut","bullets":["Q2 total revenues $338M vs. prior guidance range; net loss $261M ($5.15 diluted EPS) on $307M CDMO asset impairment.","Adjusted EBITDA of $56M improved from $(29)M a year ago; adjusted net loss per share $1.06.","FY 2023 revenue guidance revised to $1.0-1.1B (from $1.1-1.2B); adjusted EBITDA cut to $50-100M from $100-150M.","CEO transition: Haywood Miller appointed interim CEO after Robert Kramer retired; FDA approved CYFENDUS anthrax vaccine.","Sale of travel health business to Bavarian Nordic for up to $380M closed; 10-year BARDA contract for Ebanga Ebola treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-23-000152","json":"https://secwatch.observer/filing/0001367644-23-000152.json","markdown":"https://secwatch.observer/filing/0001367644-23-000152.md","text":"https://secwatch.observer/filing/0001367644-23-000152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000152/0001367644-23-000152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000152/ebs-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:16:26.236111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9a87b1fc5b046f6c048d55c1dbc3a6c36561313","claim":"Emergent BioSolutions Inc. reported the second quarter ended June 30, 2023 results: revenue Total Revenues $337.9, net income Net Loss $(261.3), EPS Net Loss per Diluted Share $(5.15).","evidence_excerpt":"by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EMERGENT BIOSO LUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2023 • Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M • Updates FY 2023 guidance and provides initial Q3 2023 forecast for total revenues GAITHERSBURG,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000152/0001367644-23-000152-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"Total Revenues $337.9"},{"label":"Net income","value":"Net Loss $(261.3)"},{"label":"EPS","value":"Net Loss per Diluted Share $(5.15)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}